Mechanisms and management of proarrhythmia

American Journal of Cardiology

Volumn 82, Issue 4 A, 1998, Pages 49I-57I

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DIGITALIS; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; IBUTILIDE FUMARATE; LIDOCAINE; MAGNESIUM SULFATE; MEXILETINE; MORACIZINE; POTASSIUM; PROCAINAMIDE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL;

ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; CONFERENCE PAPER; DEFIBRILLATION; DIGITALIS INTOXICATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART MUSCLE POTENTIAL; HEART PACING; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REENTRY TACHYCARDIA; TORSADE DES POINTES;

EID: 0032552038     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00472-X     Document Type: Conference Paper

References (70)

1. Roden DM. Clinical features of arrhythmia aggravation by antiarrhythmic drugs and their implications for basic mechanisms. Drug Dev Res 1990;19:153-172.
2. Taboulet P, Baud FJ, Bismuth C, Vicaut E. Acute digitalis intoxication - is pacing still appropriate? J Toxicol Clin Toxicol 1993;31:261-273.
3. Smith TW. Digitalis: mechanisms of action and clinical use. N Engl J Med 1988;318:358-365.
4. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996;7:999-1007.
5. Snyders DJ, Hondeghem LM, Bennett PB. Mechanisms of drug-channel interactions. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System: Scientific Foundations. New York: Raven Press, 1991:2165-2193.
6. Hondeghem LM. Antiarrhythmic agents: modulated receptor applications. Circulation 1987;75:514-520.
7. Crijns HJ, van Gelder IC, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988;62:1303-1306.
8. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-111.
9. Oetgen WJ, Tibbits PA, Abt MEO, Goldstein RE. Clinical and electrophysiologic assessment of oral flecainide acetate for recurrent ventricular tachycardia: evidence for exacerbation of electrical instability. Am J Cardiol 1983;52:746-750.
10. Winkle RA, Mason JW, Griffin JC, Ross D. Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 1981;102:857-864.
11. Morganroth J, Horowitz LN. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984;53:89B-94B.
12. Wetherbee DG, Holzman D, Brown MG. Ventricular tachycardia following the administration of quinidine. Am Heart J 1951;42:89-96.
13. Coromilas J, Saltman AE, Waldecker B, Dillon SM, Wit AL. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation 1995;91:2245-2263.
14. Bellet S, Hamden G, Somlyo A, Lara R. A reversal of the cardiotoxic effects of procainamide by molar sodium lactate. Am J Med Sci 1959;237:177-189.
15. Bajaj AK, Woosley RL, Roden DM. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation 1989;80:994-1002.
16. Chouty F, Funck-Brentano C, Landau JM, Lardoux H. Efficacité de fortes doses de lactate molaire par voie veineuse lors des intoxications au flecainide. La Presse Med 1987;16:808-810.
17. Winkelmann BR, Leinberger H. Life-threatening flecainide toxicity: a pharmacodynamic approach. Ann Intern Med 1987;106:807-814.
18. Ranger S, Talajic M, Lemery R, Roy D, Nattel S. Amplification of flecainide-induced ventricular conduction slowing by exercise. Circulation 1989;79:1000-1006.
19. Myerburg RJ, Kessler KM, Cox MM, Huikuri H, Terracall E, Interian A Jr, Fernandez P, Castellanos A. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation 1989;80:1571-1579.
20. Nattel S, Keable H, Sasyniuk BI. Experimental amitriptyline intoxication: electrophysiologic manifestations and management. J Cardiovasc Pharmacol 1983;6:83-89.
21. Xu YQ, Crumb WJ Jr, Clarkson CW. Cocaethylene, a metabolite of cocaine and ethanol, is a potent blocker of cardiac sodium channels. J Pharmacol Exp Ther 1994;271:319-325.
22. Greene HL. Interactions between pharmacologic and nonpharmacologic antiarrhythmic therapy. Am J Cardiol 1996;78(suppl):61-66.
23. Echt DS, Black JN, Barbey JT, Coxe DR, Cato EL. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation. Circulation 1989;79:1106-1117.
24. Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowey PR. Effect of Antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. PACE 1988;11:7-12.
25. CAST Investigators. Preliminary Report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
26. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
27. IMPACT Research Group. International Mexiletine and Placebo Antiarrhythmic Coronary Trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984;4:1148-1163.
28. UK Rythmodan Multicentre Study Group. Oral disopyramide after admission to hospital with suspected acute myocardial infarction. Postgrad Med J 1984;60: 98-107.
29. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW (CAST Investigators). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-788.
30. Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA (CAST Investigators). Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1991;68:1551-1555.
31. Nattel S, Pedersen DH, Zipes DP. Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981;15:80-85.
32. Wenckebach KF. Cinchona derivates in the treatment of heart disorders. JAMA 1923;81:472-474.
33. Zwillinger L. Uber die magnesiumwirkung auf das herz. Klin Wochenschr 1935;40:1429-1433.
34. Selzer A, Wray HW. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30: 17-30.
35. Jervell A, Lange-Neilsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957;54: 59-68.
36. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in eta' pediatrica. Clin Pediatr 1963;45:656-683.
37. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc 1964;54:103-106.
38. Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 1966;59:263-272.
39. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-936.
40. Roden DM. Torsades de pointes. Clin Cardiol 1993;16:683-686.
41. Ben-David J, Zipes DP. Torsades de pointes and proarrhythmia. Lancet 1993;341:1578-1582.
42. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 1995;122: 701-714.
43. Olshansky B, Martins J, Hunt S. N-acetylprocainamide causing torsades de pointes. Am J Cardiol 1982;50:1439-1439.
44. Chow MJ, Piergies AA, Bowsher DJ, Murphy JJ, Kushner W, Ruo TI, Asada A, Talano JV, Atkinson AJ. Torsades de pointes induced by N-acetylprocainamide. J Am Coll Cardiol 1984;4:621-624.
45. Lazzara R. Amiodarone and torsades de pointes. Ann Intern Med 1989;111: 549-551.
46. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
47. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72(suppl):44A-50A.
48. Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsades de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86:1376-1382.
49. Choy AMJ, Darbar D, Dell'Orto S, Roden DM. Increased sensitivity to QT prolonging drug therapy immediately after cardioversion to sinus rhythm. (Abstr.) Circulation 1996;94:I-202.
50. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc Res 1993;27: 2186-2193.
51. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986;111:1088-1093.
52. Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 1985;56:857-867.
53. Antzelevitch C, Sicouri S, Lukas A, Di Diego JM, Nesterenko VV, Liu DW, Roubache JF, Zygmunt AC, Zhang ZQ, Iodice A. Clinical implications of electrical heterogeneity in the heart: the electrophysiology and pharmacology of epicardial, M, and endocardial cells. In: Podrid PJ, Kowey PR, eds. Cardiac Arrhythmia: Mechanisms, Diagnosis, and Management. Baltimore, Md: Williams & Wilkins, 1995:88-107.
54. D'Alnoncourt CN, Zierhut W, Luderitz B. "Torsades de pointes" tachycardia: re-entry or focal activity? Br Heart J 1982;48:213-216.
55. Leichter D, Danilo P Jr, Boyden P, Rosen TS, Rosen MR. A canine model of torsades de pointes. PACE 1988;11:2235-2245.
56. Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsades de pointes. J Am Coll Cardiol 1996;28:1836-1848.
57. Roden DM, Lazzara R, Rosen MR, Schwartz PJ, Towbin JA, Vincent GM, The SADS Foundation Task Force on LQTS. Multiple mechanisms in the long QT syndrome: current knowledge, gaps, and future directions. Circulation 1996; 94:1996-2012.
58. January CT, Moscucci A. Cellular mechanisms of early afterdepolarizations. Ann NY Acad Sci 1992;644:23-32.
59. Schultz-Bahr E, Haverkamp W, Hordt M, Wedekind H, Borggrefe M, Funke H. Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long QT syndrome? (Abstr.) Circulation 1997;96:I-211.
60. Napolitano C, Priori SG, Schwartz PJ, Cantu F, Paganini V, Matteo PS, de Fusco M, Pinnavaia A, Aquaro G, Casari G. Identification of a long QT syndrome molecular defect in drug-induced torsades de pointes. (Abstr.) Circulation 1997; 96:I-211.
61. Kr. Implications for torsades de pointes and reverse use-dependence. Circulation 1996;93:407-411.
62. Compton SJ, Lux RL, Ramsay MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW. Genetically-defined therapy of inherited long-QT syndrome: correction of abnormal repolarization by potassium. Circulation 1996;94: 1018-1022.
63. Choy AM, Lang CC, Chomsky DB, Rayos GH, Wilson JR, Roden DM. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997;96:2149-2154.
64. Tzivoni D, Banai S, Schugar C, Benhorin J, Keren A, Gottlieb S, Stern S. Treatment of torsades de pointes with magnesium sulfate. Circulation 1988;77: 392-397.
65. Eldar M, Griffin JC, Abbott JA, Benditt D, Bhandari A, Herre JM, Benson DW, Scheinman MM. Permanent cardiac pacing in patients with the long QT syndrome. JAm Coll Cardiol 1987;10:600-607.
66. Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura, S, Kamiya T, Shimomura K. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 1995;26:1299-1309.
67. Waldo AL, Camm AJ, DeRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP (The SWORD Investigators). Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
68. Moller M for the DIAMOND Study Group. DIAMOND antiarrhythmic trials. Lancet 1996;348:1597-1598.
69. Morganroth J, Michelson EL, Horowitz LN, Josephson ME, Pearlman AS, Dunkman WB. Limitations of routine long-term electro cardiographic monitoring to assess ventricular ectopic frequency. Circulation 1978;58:408-414.
70. Prystowsky EN, Klein GJ. Pharmacologic therapy. Cardiac Arrhythmias: An Integrated Approach for the Clinician. New York: McGraw-Hill, 1994:382.